Focada exclusivamente no desenvolvimento, 
                                        produção e promoção de produtos farmacêuticos especializados

Notice to the Market – Management Change


BIOTOSCANA INVESTMENTS S.A. (“Company” or “GBT”) (B3: GBIO33), a leading biopharmaceutical company in Latin America, announces to its shareholders and the market in general that Mr. Leonardo Catalano was appointed as the new Chief Financial Officer of Grupo Biotoscana to replace Mrs. Raquel Balsa, effectively from August 15thonwards.

The Board of Directors and the Company thanks Raquel for her contributions and support to the Company over the past few years and wishes her success in her future challenges. At the same time the Company extends its best wishes to Leonardo Catalano in his new role.

Mr. Leonardo Calatano has over twenty years of experience in finance, auditing and international accounting and more than nine years with the group. Leonardo was the CFO of GBT Argentina for the past 3 years and before that he worked as Director at the planning and reporting corporate department in Uruguay and administrative department of GBT Argentina. Prior to joining GBT, Mr. Catalano worked at Ernst & Young, Arthur Andersen and Telecom Argentina in Argentina. Leonardo holds an Accounting degree from Universidad de Buenos Aires and an MBA fromUniversidad de San Andres.

Montevideo, August 12, 2019

Claudio Coracini
Legal representative in Brazil

To access the PDF version, please click here.

Updated on 08/12/2019 at 11:05 pm